Double radiation attack aims to stop prostate cancer bone breaks

NCT ID NCT07354594

Not yet recruiting Disease control Sponsor: Centre hospitalier de l'Université de Montréal (CHUM) Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 trial tests whether adding precise external beam radiation to standard radioligand therapy can better control metastatic prostate cancer that no longer responds to hormone therapy. About 120 participants will receive either standard treatment alone or combined with targeted radiation to under-treated tumors. The main goal is to reduce bone complications like fractures or spinal cord compression.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Lutetium-177 PSMA radioligand therapy plus external beam radiotherapy
What this could lead to: If successful, this could offer a more personalized, effective way to control metastatic prostate cancer and reduce painful bone events.
What could go wrong: This is a small, early-phase trial (120 people) testing a new combination. It may not improve outcomes or could increase side effects. Results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC CASTRATION-RESISTANT PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

castration-resistant prostate carcinoma metastatic prostate carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PROSTATE CANCER METASTATIC CASTRATION-RESISTANT

Contacts and locations

Locations

Centre Hospitalier de l'Université-de-Montréal

Montreal, Quebec, H2X 3E4, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.